OptimizeRx Corp. (OPRX)

Mixed fundamentals: strong liquidity and cash generation, but 2026 filings show a sharp revenue pullback and a return to small GAAP losses, with meaningful customer-concentration and internal-control risks. Valuation is reasonable on EV/Sales and EV/EBITDA and analyst targets imply upside, but the discounted-cash-flow outputs are not supportive; best treated as watchlist pending clearer top-line stabilization.

No material first-party catalysts in the actionable window — OptimizeRx's trailing-30d PR flow is routine and non-material (AI product-iteration expansion, advisor appointment, conference appearance) — media sentiment in the 14-day window is light and near-flat (aggregator +0.03, n=3), the 30–90d baseline is too sparse for a determinate delta, and retail coverage is absent. Red-Flag Screen clean; the setup is Absent rather than distressed.

Trend frame is split: price closed 7.72 on 09-14, back above the SMA50 (7.13), EMA9/EMA21 (7.58/7.59), DEMA/TEMA and the daily VWAP (7.61), but still below the SMA20 (7.80) and SMA200 (8.16). Momentum is repairing but unconfirmed: RSI 54 recovering from 43, Williams %R -42 from -99, MACD line positive at 0.09 yet under its signal (0.20) with a -0.11 histogram that is narrowing; ADX 46 indicates a strong trend, and with price above the 50-day the bias is up. The 09-14 reversal day (+4.3%) off the 7.1 support shelf is a genuine bullish impulse, but the below-20/200-day position and still-negative MACD histogram cap the read at 3 (mixed). Tradability is independently zeroed by the qualitative override (score 2) and by liquidity far below both floors.